Sorvasta

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sorvasta

What is Sorvasta?

Sorvasta is a pharmaceutical medication belonging to a class of drugs known as statins, or HMG-CoA reductase inhibitors. Its primary function is to regulate the levels of lipids (fats) in the blood by managing how the body produces and processes cholesterol.

Therapeutic Purpose

The medication is used to manage high levels of cholesterol and triglycerides. Specifically, it works to:

  • Lower LDL cholesterol: Often referred to as "bad" cholesterol, which can build up in the walls of the arteries.
  • Lower triglycerides: Another type of fat in the blood that can contribute to cardiovascular risk when levels are too high.
  • Raise HDL cholesterol: Known as "good" cholesterol, which helps remove other forms of cholesterol from the bloodstream.

Mechanism of Action

Sorvasta contains the active substance rosuvastatin. It functions by blocking a specific enzyme in the liver that is responsible for the synthesis of cholesterol. By reducing the internal production of cholesterol, the medication encourages the liver to take up more LDL cholesterol from the blood, thereby reducing overall circulating levels.

Clinical Role

Beyond just treating high cholesterol (hypercholesterolemia), Sorvasta is utilized in the management of long-term cardiovascular health. It is often prescribed to individuals who have an increased risk of heart-related events, such as heart attacks or strokes, due to factors like atherosclerosis (the hardening and narrowing of the arteries).

This medication is typically intended for use in conjunction with a cholesterol-lowering diet and other lifestyle modifications when these measures alone are not sufficient to achieve target lipid levels.

Regulatory References

  1. NIH StatPearls: Rosuvastatin
  2. MedlinePlus: Rosuvastatin Drug Information

What side effects are possible with Sorvasta?

Possible Side Effects and Safety Information

The official documentation for Rosuvastatin (Sorvasta) outlines a safety profile categorized by the affected body system and the frequency of occurrence, as defined by regulatory standards.

Frequency-Classified Adverse Reactions

Adverse reactions are classified based on pooled data from clinical studies and post-marketing surveillance:

  • Common (occurring in 1/100 to < 1/10 patients): These reactions include myalgia (muscle pain), headache, dizziness, nausea, constipation, abdominal pain, and asthenia (weakness). New-onset diabetes mellitus is also listed as a common effect.
  • Uncommon (occurring in 1/1,000 to < 1/100 patients): Pruritus (itching), rash, and urticaria (hives) are included in this category, alongside proteinuria (protein in the urine), which is typically documented as a transient effect.
  • Rare (occurring in 1/10,000 to < 1/1,000 patients): Rare events include pancreatitis (inflammation of the pancreas), myopathy (muscle disease), and rhabdomyolysis (severe muscle breakdown). Increased hepatic transaminases are also documented as rare.

Serious Adverse Reactions and Safety Constraints

The most clinically significant documented adverse reactions involve the musculoskeletal and hepatobiliary systems. Rhabdomyolysis is officially documented as a severe complication that can lead to acute renal injury. Hepatitis and jaundice are documented very rare events indicating serious liver risk. The medicine is officially contraindicated in patients with active liver disease.

Safety notes specify that systemic exposure is increased in patients with moderate to severe renal impairment and in individuals of Asiatic origin, which influences its official risk assessment for these populations.

Overdose and Emergency Response

The official regulatory profile for Sorvasta (Rosuvastatin) overdose focuses entirely on mandated emergency actions and clinical management, as no unique overdose syndrome is formally documented in prescribing information. The primary guidance states that there is no specific treatment or antidote known for Rosuvastatin overdosage.

If a suspected or confirmed overdosage occurs, it is required that immediate medical attention be sought. Patients must contact a physician, go to the nearest hospital emergency room right away, or call a regional poison control centre for guidance on management. This urgent action is necessary because the official strategy centers on close clinical monitoring and comprehensive support.

In the event of overdosage, the patient should be treated symptomatically, and supportive measures instituted as required based on the patient’s clinical status. Standard procedures, such as hemodialysis, are noted in regulatory documents as not significantly enhancing the clearance of rosuvastatin from the body. Consequently, management relies on supportive care under close medical supervision to address any emerging signs or symptoms. This approach reflects the uniform and critical need for professional medical intervention upon suspected overdose.

Therapeutic Uses of Sorvasta

Quick Facts: Sorvasta (Rosuvastatin)

  • Goal of Therapy: To help manage elevated levels of cholesterol and triglycerides in the blood.
  • Key Indication: Used in conjunction with diet and exercise when lifestyle measures alone are not sufficient.
  • Benefit Profile: May help reduce the risk of major adverse cardiovascular events.

Sorvasta is a medication used to influence blood lipid profiles in adult and pediatric patients with certain conditions. The primary therapeutic use is as an adjunct to diet to help manage elevated levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C, often referred to as 'bad' cholesterol), and triglycerides. It also may support an increase in high-density lipoprotein cholesterol (HDL-C, often referred to as 'good' cholesterol).

For adults with primary hyperlipidemia or mixed dyslipidemia, Sorvasta may be utilized to help lower these elevated lipid levels. In addition to cholesterol management, the drug is also indicated to contribute to the reduction of risk for major cardiovascular events, such as stroke and myocardial infarction, in individuals who have an increased risk profile. The treatment may also help slow the progression of atherosclerosis (the buildup of fatty deposits in arteries) in adults as part of a comprehensive strategy. Specific use is also approved for patients with certain genetic conditions, including homozygous and heterozygous familial hypercholesterolemia.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Sorvasta (rosuvastatin) is a prescription medicine and is not suitable for everyone. Eligibility for treatment is strictly defined by regulatory authorities based on a patient's pre-existing health status, age, and reproductive status.

Contraindicated Populations

Official regulatory documents contraindicate the use of Sorvasta in certain patient groups:

  • Patients with a known hypersensitivity or allergic reaction to rosuvastatin or any other ingredient in the medicine.
  • Patients who have active liver disease, including those with unexplained, persistent elevations of liver transaminase enzymes.
  • Pregnant women or women who may become pregnant.
  • Breastfeeding women.

Eligibility Restrictions and Special Considerations

  • Females of reproductive potential are advised to use effective contraception during treatment.
  • Pediatric use is restricted to children aged 7 years and older with Homozygous Familial Hypercholesterolemia (HoFH) or children aged 8 years and older with Heterozygous Familial Hypercholesterolemia (HeFH), subject to specific clinical criteria.
  • Patients with severe renal impairment (kidney disease) not on hemodialysis may be restricted to a lower maximum dose, such as 10 mg or less.
  • The highest 40 mg dose is contraindicated in patients with predisposing factors for myopathy, which include kidney impairment, advanced age, or uncontrolled hypothyroidism.

What should I know about interactions with other medicines?

The official interaction profile for Sorvasta (Rosuvastatin) is primarily defined by its effects on drug transport and the potential for additive pharmacodynamic risks, as documented in regulatory information.

Pharmacokinetic Interactions

Most clinically significant interactions are pharmacokinetic, resulting from the inhibition of drug transporters OATP1B1 and BCRP. Co-administration with potent inhibitors, such as Ciclosporin and certain Anti-viral medicines (e.g., Lopinavir/Ritonavir), is officially documented to significantly increase rosuvastatin's systemic exposure (AUC and Cmax). This documented exposure increase leads to mandatory restrictions, including dose limitations or, in some cases, contraindication for co-use.

Conversely, Aluminum and Magnesium Hydroxide Antacids reduce rosuvastatin absorption. To mitigate this effect, official labeling specifies that rosuvastatin must be administered at least two hours after the antacid.

Pharmacodynamic Interactions

Co-administration with other lipid-modifying agents, including Fibrates (such as Gemfibrozil) and Lipid-modifying doses of Niacin (greater than 1 g/day), carries a documented additive pharmacodynamic risk of skeletal muscle effects (myopathy). Additionally, the use of Sorvasta with Coumarin anticoagulants is officially noted to prolong the International Normalized Ratio (INR).

Population-Specific Notes

Official labeling documents that systemic exposure is increased in patients with severe renal impairment and in Asian patients, which is an important consideration when evaluating co-administered medicines.

Mechanism of Action

The drug's primary action involves acting as a competitive and reversible inhibitor of the enzyme HMG-CoA Reductase inside the liver. This molecular blockade controls the Mevalonate pathway, which is the critical step for endogenous cholesterol synthesis. This mechanism directly initiates a drop in the liver cell's cholesterol supply, which is the necessary trigger for the subsequent systemic effects.

Following the initial molecular blockade, the liver cell compensates by drastically increasing the number of LDL Receptors on its surface. This cellular response enhances the liver’s ability to capture and clear circulating Low-Density Lipoprotein Cholesterol (LDL-C) particles from the plasma, which results in the systemic reduction of circulating LDL-C.

Sorvasta also modulates key non-sterol intermediates of the synthesis pathway, which indirectly influences the signaling that regulates vascular tone and endothelial function. This mechanism is associated with a decrease in inflammatory markers, such as C-Reactive Protein (CRP), as a consequence of pathway modulation, and modulates function within vascular pathways.

Dosage and Administration Information

How to Use Sorvasta: Official Administration Guidelines

Sorvasta (rosuvastatin) is a medication administered through the oral route as a film-coated tablet. The usage pattern is standardized to a once-daily schedule, which can be taken at any time of day and with or without food. This high-level pattern of use supports consistent dosing for long-term lipid management.

Standard dosing is initiated based on patient needs, typically starting at 5 mg, 10 mg, or 20 mg once daily. The standard maintenance dose ranges from 5 mg to 40 mg. The maximum recommended dose is 40 mg once daily, which is reserved for patients who have not achieved their targeted cholesterol levels on a 20 mg dose.

Administration Requirements

Usage Constraint Official Instruction
Tablet Handling Tablets must be swallowed whole and should not be crushed, chewed, or dissolved.
Dose Adjustment Dose changes, if required, should only occur after a minimum interval of 2 to 4 weeks following a lipid assessment.
Missed Dose If a daily dose is missed, skip that dose entirely and take the next dose at the regular scheduled time; do not take a double dose.

Population-Specific Dosing

Specific dosage limits are detailed for certain patient groups. For individuals with severe renal impairment (kidney disease), the starting dose is restricted to 5 mg once daily, and the daily dose must not exceed 10 mg. Additionally, a 5 mg starting dose should be considered for patients of Asian descent and may be recommended for older adults (aged 70 years and above).

Recent Clinical Evidence

Research evidence / Overview of studies for Sorvasta

The body of research on Sorvasta has focused on its evaluation in conditions characterized by elevated cholesterol levels and research exploring patterns related to major cardiovascular outcomes. Evidence is drawn from formal clinical studies, including large-scale randomized controlled trials (RCTs). Studies show what has been observed, but research does not determine whether an individual will respond similarly.


1. Evidence for use in Hypercholesterolemia and Mixed Dyslipidemia

This section summarizes short-term RCTs in adults with hypercholesterolemia, monitoring outcomes like Low-Density Lipoprotein Cholesterol (LDL-C), Total Cholesterol, and Triglycerides. Trials documented mean percentage changes in these biomarkers from baseline. Comparative reports described patterns of measurement differences between Sorvasta and other treatments.


2. Evidence for use in Reducing Cardiovascular Risk

Research examined associations with patterns of event rates related to major cardiovascular outcomes. This involved large, long-term trials designed to track Major Adverse Cardiovascular Events (MACE)—such as heart attack or stroke—in high-risk populations. Outcomes also monitored changes in inflammatory biomarkers like high-sensitivity C-Reactive Protein (hsCRP).


3. Long-Term Evidence and Durability of Study Findings

Studies involved follow-up durations extending over several years, with analysis points designed to monitor MACE occurrence. Open-label extension studies were used for extended observation. While these studies contribute to the evidence landscape, long-term effects are not yet fully established across all studied populations.


4. Evidence in Specific Patient Populations

Sorvasta was evaluated in pediatric patients (children and adolescents) specifically diagnosed with Heterozygous Familial Hypercholesterolemia. Research also monitored high-risk adult populations with specific risk factor profiles. Findings describe group patterns, but results apply only to the populations studied.


5. Evidence Gaps and Areas of Uncertainty

Limitations include a lack of dedicated long-term comparative outcomes data against other high-intensity statins. Also, some studies in high-risk groups, like patients with end-stage renal disease (ESRD), have reported mixed findings regarding event rates. Specific outcomes studies are not yet available for a wide range of comorbid conditions.

Frequently Asked Questions (FAQ)

Common questions about Sorvasta (FAQ)


Q: Is Sorvasta the same as other statin medications?

Sorvasta (rosuvastatin) belongs to the family of medicines known as statins (HMG-CoA reductase inhibitors). While all statins work to lower cholesterol, official regulatory documents note that rosuvastatin is classified as a hydrophilic compound. This means it is water-soluble, which can affect its distribution and metabolism in the body when compared to other types of statins.


Q: Why did my doctor prescribe Sorvasta instead of Lipitor?

Official information indicates that rosuvastatin is a highly potent statin used to reduce LDL-C (sometimes called 'bad cholesterol'). It is also indicated for the prevention of major cardiovascular events, such as heart attack and stroke, in people considered to be at high risk. These factors, alongside a patient's overall lipid goals, are general considerations that may influence prescribing choices.


Q: Is Sorvasta safe for older adults to take?

Regulatory information indicates that Sorvasta can be used in older adults (generally those aged 65 and above). However, special consideration is given to this group, and a lower starting dose may be recommended. The highest dose of 40 mg is typically restricted in this population if there are other factors that increase the risk of muscle side effects.


Q: Is it normal to feel a bit dizzy when first starting Sorvasta?

Yes, regulatory documents list dizziness as a common adverse reaction associated with Sorvasta. A 'common' reaction means it was observed in a significant percentage of patients in clinical studies. Patients experiencing persistent or concerning symptoms should report them to their healthcare provider.


Q: Are there any known long-term effects on muscles from Sorvasta?

Muscle pain (myalgia) is a common side effect of Sorvasta. In rare instances, official safety information reports a serious condition called Immune-Mediated Necrotizing Myopathy (IMNM). This specific condition can be characterized by muscle weakness and other signs that may persist even after the medicine has been discontinued.


Q: Does continuous use of Sorvasta lead to needing higher doses?

Official administration guidelines state that the Sorvasta dose is adjusted based on an individual patient's lipid response to the treatment. Dose changes, if needed, should only be made after re-testing cholesterol levels to assess the response, not as a continuous escalation due to tolerance.


Q: Why do some people stop taking Sorvasta after a few months?

Official documentation advises that the drug should be stopped if a patient develops certain complications. These include signs of myopathy (muscle disease), such as muscle pain accompanied by high blood markers, or if the patient develops active liver disease. These are documented medical reasons for treatment discontinuation.


Q: Is Sorvasta used for anything besides high cholesterol?

Yes, Sorvasta (rosuvastatin) has regulatory approval for treating other specific lipid disorders in addition to high cholesterol (hypercholesterolemia). These include high triglyceride levels (hypertriglyceridemia) and primary dysbetalipoproteinemia, as an adjunct to diet.


Q: Do I need to change my diet while taking Sorvasta?

According to the official prescribing information, Sorvasta is consistently indicated as an adjunct to diet. This means the medicine is intended to supplement and support a reduced-fat or cholesterol-lowering diet, and is not meant to replace dietary changes.


Q: How often do I need blood tests while on Sorvasta?

Regulatory guidelines indicate that a patient's cholesterol levels should be tested and analyzed within two to four weeks after starting Sorvasta or after any dose adjustments. This is done to assess lipid response and guide any potential dose adjustment.


Q: Why does Sorvasta sometimes cause stomach upset?

Official adverse reaction listings document that common side effects of Sorvasta include gastrointestinal issues such as constipation, abdominal pain, and nausea. These are common patterns observed frequently in patient studies.


Q: Can women who are planning to become pregnant take Sorvasta?

No, the official prescribing information advises against this. Sorvasta is strictly contraindicated (not allowed) in pregnant women, and the medicine is officially contraindicated during pregnancy and use is typically discontinued if pregnancy is detected. Women who are of reproductive age must use effective contraception throughout the course of therapy.


Q: What should I do if I feel unusually tired after starting Sorvasta?

Official safety documents list asthenia (weakness/unusual tiredness) as a common side effect. Official safety information advises patients to promptly report unexplained or persistent muscle symptoms (such as pain, tenderness, or weakness) to their healthcare provider.


Q: Are there any generic versions of Sorvasta available?

Yes, the active ingredient in Sorvasta, which is rosuvastatin calcium, is officially available as a generic drug product. Generic versions are typically listed on national regulatory databases and contain the same active ingredient as the brand-name medicine.


Q: How does Sorvasta differ from a fiber supplement for cholesterol?

Sorvasta is a prescription medication that works by blocking a key enzyme in the liver to stop the internal production of cholesterol. Fiber supplements are non-prescription products. Official information warns that fiber-containing antacids may interact with Sorvasta, potentially affecting its absorption, requiring special administration timing.


Q: Do certain herbal supplements interact badly with Sorvasta?

Official guidance advises that patients should inform their doctor or pharmacist about all products they are taking. This includes any herbal remedies, vitamins, or nutritional supplements, as official information notes that these may affect the safety or effectiveness of the medicine.


Q: Why is the time of day I take Sorvasta important?

According to the official dosage guidelines, Sorvasta can be taken at any time of day, whether it is morning, afternoon, or evening. It can also be taken with or without food. The goal is to take the dose consistently each day for best management.


Q: Will Sorvasta interfere with my daily vitamins?

Regulatory documents recommend that patients disclose all supplements, including vitamins, to their healthcare professional. This is because some vitamins or supplements may contain substances that could potentially affect the way Sorvasta is absorbed or processed by the body.


Q: Are the side effects of Sorvasta reversible if I stop taking it?

The majority of documented side effects, such as general muscle pain and headache, are typically reversible and resolve after the medication is discontinued. However, official warnings mention that in rare cases, a serious muscle condition called Immune-Mediated Necrotizing Myopathy may persist after stopping the drug.


Q: Does Sorvasta require a prescription in all countries?

In the United States, Sorvasta is classified as a Human Prescription Drug. Globally, statin medications are generally designated as prescription-only drugs, meaning they require authorization from a licensed healthcare provider before they can be dispensed.


Q: Is Sorvasta considered a first-line treatment for high cholesterol?

Yes, clinical information widely confirms that statins, including rosuvastatin (Sorvasta), are generally recommended as first-line therapy. They are used in combination with diet changes to manage elevated cholesterol and reduce cardiovascular risk.


Q: Will taking Sorvasta make my cholesterol levels return to normal?

Sorvasta is indicated to reduce harmful lipids like LDL-C and other factors associated with high cholesterol. Treatment is managed by a healthcare professional with the goal of reaching an individualized lipid level target, which aligns with official guidelines for cardiovascular risk reduction.

How should Sorvasta be stored and disposed of?

How to Store and Dispose of Sorvasta

Sorvasta (rosuvastatin) tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C.

Storage Requirements

The product must be protected from moisture and should be kept in the original container to protect it from light. If supplied in a bottle, the lid must be kept tightly closed. It is mandatory to store Sorvasta out of the sight and reach of children and not use the medicine after the labeled expiry date.

Disposal

Unused or expired Sorvasta must not be thrown away with household waste or down the drain. Disposal must be performed according to local regulations to ensure proper environmental protection. Consult a pharmacist for guidance on safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sorvasta found in:

A-Z Index: